TargetMol

TGFβRI-IN-3

Product Code:
 
TAR-T9523
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9523-1mg1mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-1mL1 mL * 10 mM (in DMSO)£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-5mg5mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-10mg10mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-25mg25mg£563.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-50mg50mg£838.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-100mg100mg£1,171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9523-500mg500mg£2,263.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
TGFβRI-IN-3 is a highly selective TGFβR1 inhibitor with potential application in immuno-oncology.
CAS:
T9523
Formula:
C28H23N3O2S
Molecular Weight:
465.57
Pathway:
Stem Cells
Purity:
0.994
SMILES:
O=S(C1=CC=C(C2=CC(N=CC=C3NC4=CC(C5=CC=CC(C)=C5)=NC=C4)=C3C=C2)C=C1)(C)=O
Target:
TGF-beta/Smad

References

Kharbanda A, et al. Discovery of 4-aminoquinolines as highly selective TGF?R1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology [published online ahead of print, 2021 Aug 12]. Eur J Med Chem. 2021;225:113763.